BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31343482)

  • 1. Inv(11)(q21q23); KMT2A-MAML2, a Recurrent Genetic Abnormality in T-Cell Therapy-related Acute Lymphoblastic Leukemia.
    Mariani RA; Silva M; Caparelli E; Jennings LJ; Yap KL; Leuer KM; Weinstein J; Gong S
    J Pediatr Hematol Oncol; 2020 May; 42(4):e258-e261. PubMed ID: 31343482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous inv(11)(q21q23) and MLL gene rearrangement in two patients with myeloid neoplasms.
    Tang G; Lu X; Wang SA; Roney EK; Zhang L; Hu S; Lu G; Medeiros LJ; Patel A
    Int J Clin Exp Pathol; 2014; 7(6):3196-201. PubMed ID: 25031740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acute lymphoblastic leukemia with inv(11)(q21q23.3)/KMT2A::MAML2 fusion gene progressed to acute myeloid leukemia: a case report].
    Zhang Y; Ni JB; Zhang QJ; Hui S; Wang CF; Wang T
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):196. PubMed ID: 38604799
    [No Abstract]   [Full Text] [Related]  

  • 4. First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia.
    Tandon S; Shago M; Davidson S; Kanwar N; Fuligni F; Shlien A; Whitlock J; Villani A; Abla O
    Cancer Genet; 2020 Oct; 248-249():31-33. PubMed ID: 32992102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pediatric case of secondary T-cell acute lymphoblastic leukemia with KMT2A-MAML2 developing after hepatoblastoma treatment.
    Takahashi Y; Terui K; Chinen Y; Tandai S; Kudo K; Sasaki S; Tono C; Taki T; Ito E
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28033. PubMed ID: 31599492
    [No Abstract]   [Full Text] [Related]  

  • 6. First case of B ALL with KMT2A-MAML2 rearrangement: a case report.
    Menu E; Beaufils N; Usseglio F; Balducci E; Lafage Pochitaloff M; Costello R; Gabert J
    BMC Cancer; 2017 May; 17(1):363. PubMed ID: 28535805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel KMT2A-ACTN2 fusion in infant B-cell acute lymphoblastic leukemia.
    Yoshida M; Nakabayashi K; Ogata-Kawata H; Osumi T; Tsujimoto SI; Shirai R; Yoshida K; Okamura K; Matsumoto K; Kiyokawa N; Tomizawa D; Hata K; Kato M
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27821. PubMed ID: 31115144
    [No Abstract]   [Full Text] [Related]  

  • 8. Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
    Gestrich CK; Sadri N; Sinno MG; Pateva I; Meyerson HJ
    Br J Haematol; 2020 Oct; 191(2):e61-e64. PubMed ID: 32729113
    [No Abstract]   [Full Text] [Related]  

  • 9. Inv(11)(q21q23) fuses MLL to the Notch co-activator mastermind-like 2 in secondary T-cell acute lymphoblastic leukemia.
    Metzler M; Staege MS; Harder L; Mendelova D; Zuna J; Fronkova E; Meyer C; Flohr T; Bednarova D; Harbott J; Langer T; Gesk S; Trka J; Siebert R; Dingermann T; Marschalek R; Niemeyer C; Rascher W
    Leukemia; 2008 Sep; 22(9):1807-11. PubMed ID: 18337764
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of a novel fusion gene MLL-MAML2 in secondary acute myelogenous leukemia and myelodysplastic syndrome with inv(11)(q21q23).
    Nemoto N; Suzukawa K; Shimizu S; Shinagawa A; Takei N; Taki T; Hayashi Y; Kojima H; Kawakami Y; Nagasawa T
    Genes Chromosomes Cancer; 2007 Sep; 46(9):813-9. PubMed ID: 17551948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants.
    Fazio G; Bardini M; De Lorenzo P; Grioni A; Quadri M; Pedace L; Corral Abascal L; Palamini S; Palmi C; Buldini B; Vinti L; Parasole R; Barisone E; Zecca M; Favre C; Locatelli F; Conter V; Rizzari C; Valsecchi MG; Biondi A; Cazzaniga G
    Blood; 2021 Apr; 137(14):1980-1984. PubMed ID: 33512459
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.
    Qing X; Panosyan E; Yue C; Ji P; Gotesman M; French S; Cai J
    Exp Mol Pathol; 2017 Dec; 103(3):263-266. PubMed ID: 29155023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.
    Haddox CL; Mangaonkar AA; Chen D; Shi M; He R; Oliveira JL; Litzow MR; Al-Kali A; Hogan WJ; Elliott MA
    Blood Cancer J; 2017 Sep; 7(9):e607. PubMed ID: 29016570
    [No Abstract]   [Full Text] [Related]  

  • 14. t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?
    Xie W; Tang G; Wang E; Kim Y; Cloe A; Shen Q; Zhou Y; Garcia-Manero G; Loghavi S; Hu AY; Wang S; Bueso-Ramos CE; Kantarjian HM; Medeiros LJ; Hu S
    Ann Hematol; 2020 Mar; 99(3):487-500. PubMed ID: 32006151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996.
    Piciocchi A; Messina M; Elia L; Vitale A; Soddu S; Testi AM; Chiaretti S; Mancini M; Albano F; Spadano A; Krampera M; Bonifacio M; Cairoli R; Vetro C; Colella F; Ferrara F; Cimino G; Bassan R; Fazi P; Vignetti M
    Am J Hematol; 2021 Sep; 96(9):E334-E338. PubMed ID: 34048072
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.
    Peterson JF; Sukov WR; Pitel BA; Smoley SA; Pearce KE; Meyer RG; Williamson CM; Smadbeck JB; Vasmatzis G; Hoppman NL; Greipp PT; Baughn LB; Ketterling RP
    Genes Chromosomes Cancer; 2019 Aug; 58(8):567-577. PubMed ID: 30707474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy-related B-lymphoblastic leukemia associated with Philadelphia chromosome and MLL rearrangement: Single institution experience and the review of the literature.
    Matnani R; Parekh V; Borate U; Brazelton J; Reddy V; Peker D
    Pathol Int; 2015 Oct; 65(10):536-40. PubMed ID: 26259760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term remission of therapy-related acute myeloid leukemia with a new t(11;18)(q23;q21.2) translocation and KMT2A-ME2 (MLL-ME2) fusion gene.
    Szotkowski T; Jarošová M; Zimmermannová O; Meyer C; Marschalek R; Zuna J; Hubáček J; Indrák K
    Cancer Genet; 2015 Dec; 208(12):610-4. PubMed ID: 26556690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukemia with t(10;11)(p11-12;q23.3): Results of Russian Pediatric AML registration study.
    Zerkalenkova E; Lebedeva S; Kazakova A; Tsaur G; Starichkova Y; Timofeeva N; Soldatkina O; Aprelova E; Popov A; Ponomareva N; Baidun L; Meyer C; Novichkova G; Maschan M; Maschan A; Marschalek R; Olshanskaya Y
    Int J Lab Hematol; 2019 Apr; 41(2):287-292. PubMed ID: 30624859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.
    Gardner R; Wu D; Cherian S; Fang M; Hanafi LA; Finney O; Smithers H; Jensen MC; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2016 May; 127(20):2406-10. PubMed ID: 26907630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.